跳转至内容
Merck
CN

S2944

Sigma-Aldrich

Anti-SMN antibody, Mouse monoclonal

clone 2B1, purified from hybridoma cell culture

登录查看公司和协议定价

别名:
Anti-Survival of Motor Neurons
MDL编号:
UNSPSC代码:
12352203
NACRES:
NA.41

生物来源

mouse

质量水平

偶联物

unconjugated

抗体形式

purified from hybridoma cell culture

抗体产品类型

primary antibodies

克隆

2B1, monoclonal

形式

buffered aqueous solution

种属反应性

Xenopus, human, mouse

浓度

~2 mg/mL

技术

microarray: suitable
western blot: 2-4 μg/mL using A431 cell extract

同位素/亚型

IgG1

运输

dry ice

储存温度

−20°C

靶向翻译后修饰

unmodified

基因信息

一般描述

Mouse monoclonal clone 2B1 anti-SMN antibody recognizes human, mouse, and Xenopus survival of motor neurons proteins.

特异性

The antibody recognizes human, mouse, and Xenopus SMN.

免疫原

recombinant human SMN

应用

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Enzyme-linked immunosorbent assay (1 paper)
Mouse monoclonal clone 2B1 anti-SMN antibody is an important tool for studying the role of the survival of motor neurons protein in nuclear processes and spinal muscular atrophy (SMA). It may be used in immunoblotting (~35 kDa), immunoprecipitation, and immunocytochemistry.

生化/生理作用

Survival of Motor Neurons (SMN) complex is important in various biological processes, such as assembly and restructuring of spliceosomal small nuclear ribonucleoproteins (snRNPs), pre mRNA splicing and transcription. Spinal muscular atrophy (SMA) is caused by reduced expression or mutations in the survival of motor neurons (SMN) protein. Deletion or mutation in the telomeric copy (SMN1) causes the SMA phenotype. The severity of SMA is in direct correlation with the expression level of the SMN protein, either from the SMN1 gene or a different spliced form of SMN from the SMN2 gene. The SMN complex interacts with various protein substrates such as Sm and Lsm proteins of the spliceosomal snRNPs, fibrillarin, GAR1, RNA helicase A, the human hnRNP proteins (hnRNPQ, U and R), coilin and p53.

外形

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15mM sodium azide.

储存及稳定性

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in "frostfree" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

常规特殊物品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?
Burghes AHM and Beattie CE
Nature Reviews. Neuroscience, 10(8), 597-597 (2009)
Dione T Kobayashi et al.
PloS one, 6(8), e24269-e24269 (2011-09-10)
Genetic defects leading to the reduction of the survival motor neuron protein (SMN) are a causal factor for Spinal Muscular Atrophy (SMA). While there are a number of therapies under evaluation as potential treatments for SMA, there is a critical
Thomas O Crawford et al.
PloS one, 7(4), e33572-e33572 (2012-05-05)
The universal presence of a gene (SMN2) nearly identical to the mutated SMN1 gene responsible for Spinal Muscular Atrophy (SMA) has proved an enticing incentive to therapeutics development. Early disappointments from putative SMN-enhancing agent clinical trials have increased interest in
Matthew M Seavey et al.
Current protocols in pharmacology, Chapter 5, Unit 5-Unit 5 (2011-09-22)
Systemic Lupus Erythematosus (SLE) is a debilitating and often fatal autoimmune disease that involves multiple organ systems. It can develop for years before being diagnosed. Current treatments for SLE usually involve the use of cytotoxic or immunosuppressive agents that can
Amparo Garcia-Lopez et al.
Nature communications, 9(1), 2032-2032 (2018-05-26)
Modification of SMN2 exon 7 (E7) splicing is a validated therapeutic strategy against spinal muscular atrophy (SMA). However, a target-based approach to identify small-molecule E7 splicing modifiers has not been attempted, which could reveal novel therapies with improved mechanistic insight.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门